

BRIAN SANDOVAL
Governor



RICHARD WHITLEY, MS
Director

MARTA JENSEN
Administrator

DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 East William Street, Suite 101
Carson City, Nevada 89701
Telephone (775) 684-3676 • Fax (775) 687-3893
<http://dhcfp.nv.gov>

**Division of Health Care Financing and Policy
Notice of Meeting to Solicit Public Comments and Intent to Act
Upon Amendments to the Medicaid Services Manual (MSM)**

**Public Hearing December 14, 2017
Minutes**

Date and Time of Meeting: December 14, 2017 at 1:08 PM

Name of Organization: State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)

Place of Meeting: Nevada State Legislative Building
401 S. Carson Street, Room 3137
Carson City, Nevada 89701

Place of Video Conference: Grant Sawyer Office Building
555 E. Washington Avenue, Room 4406
Las Vegas, Nevada 89101

Teleconference: North (775) 687-0999
South (702) 486-5260

Access Code: 43606

Attendees

In Carson City, NV

Lynne Foster, DHCFP
Cody Phinney, DHCFP
Holly Long, DHCFP

Darrell Faircloth, SDAG
Carl Jeffery, OptumRx

Introduction:

Ms. Lynne Foster, Chief of Division Compliance, DHCFP, opened the Public Hearing introducing herself, Ms. Cody Phinney, Deputy Administrator of the DHCFP and Mr. Darrell Faircloth, Senior Deputy Attorney General (SDAG).

Ms. Foster – The notice for this public hearing was published on November 13, 2017 in accordance with the Nevada Revised Statute 422.2369.

1. Public Comment

- No Comments.

2. For Possible Action: Review and approve meeting minutes from the November 16, 2017 public hearing

The minutes for the November 16, 2017 were not brought up for approval. They will be up for approval on the December 21, 2017 public hearing.

3. Discussion of proposed changes to MSM Chapter 1200 – Prescribed Drugs

Ms. Holly Long and Mr. Carl Jeffery:

The DHCFP proposes revisions to MSM Chapter 1200, Appendix A, based on recommendations approved at the August 24, 2017 Drug Use Review (DUR) Board meeting. The changes include the clinical criteria for Exondys 51® (eteplirsen) and Spinraza® (nusinersen) be added to Chapter 1200, and that Siliq® (broadalumab) be added to the list of Immunomodulators. The Board also removed the prior authorization criteria for COX-2 Inhibitors. The Board recommended the removal of the specific brand names under the therapeutic class of Antiemetics.

The following maintenance edits were made: Olysio® (simeprevir) was removed and “Previously reviewed by the DUR Board: April 28, 2016” was added to the section titled “Narcotic Withdrawal Therapy Agents.”

The following Provider Types (PT) will potentially be affected by this change: Outpatient Hospital (PT 12); Nursing Facility (PT 19); Pharmacy (PT 28); Physician/Osteopath (PT 20); Advanced Practice Registered Nurse (PT 24); Hospice (PT 64); Hospice, Long Term Care (PT 65); Physician’s Assistant (PT 77).

Financial Impact on Local Government: A change in expenditures cannot be calculated at this time.

The effective date is January 1, 2018.

Ms. Long and Mr. Jeffery fully read in all changes and corrections. At the end of their presentation, Ms. Foster asked Ms. Phinney and Mr. Faircloth if they had any questions or comments.

Ms. Phinney's Comments:

- No Comments.

Mr. Faircloth's Comments:

- No Comments.

Public Comments:

- No Comments.

Ms. Foster – Recommended the Deputy Administrator approve as submitted with the following changes read in:

- Appendix A, Page 25 (L) – change the generic name for Siliq® “infliximab” to “brodalumab.”

Ms. Phinney – Approved as submitted.

Ms. Foster – Closed the Public Hearing for the MSM Chapter 1200 – Prescribed Drugs.

4. General Public Comments

- No Comments.

5. Adjournment

There were no further comments and Ms. Foster adjourned the public hearing at 1:20 PM.

**An Audio (CD) version of this meeting is available through the DHCFP Compliance office. For more detailed information on any of the handouts, submittals, testimony and or comments please contact Ellen Felsing at Ellen.Felsing@dncfp.nv.gov or (775) 684-3684 with any questions.*